Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Klinik Indonesia JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) JSFK (Jurnal Sains Farmasi & Klinis) Keluwih: Jurnal Kesehatan dan Kedokteran Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Pharmaceutical Sciences and Research (PSR)
Bobby Presley, Bobby
1) Departemen Farmasi Klinis Dan Komunitas, Faculty Of Pharmacy, University Of Surabaya 2) Pusat Informasi Obat Dan Layanan Kefarmasian (PIOLK), Faculty Of Pharmacy, University Of Surabaya
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 11 Documents
Search

 1   2 
The Chemotherapy Use and Adverse Effects of Patients with Lung Cancer at Regional General Hospital in Surabaya, Indonesia Yulia, Rika; Kirtishanti, Aguslina; Wijono, Heru; Setiawan, Eko; Presley, Bobby; Go, Tjie Kok; Mayani, Ni Putu Irma; Febriani, Anna; Jaya, Halim Priyahau; Herawati, Fauna
Pharmaceutical Sciences and Research
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

In Indonesia, lung cancer is the leading cause of death related to cancer, according to Global Cancer Observatory. Chemotherapy is the most common treatment since it works systemically and can prevent cancer cells from spreading to other organs. Cytotoxicity of chemotherapy can also put patients at high risk of experiencing adverse effects. This study aimed to evaluate the congruity of chemotherapy use with treatment recommendations and the profile of adverse effects, not only acute but also delayed adverse drug reactions. This prospective observational study involved 41 adult patients with lung cancer who received chemotherapy. Data is collected through patients’ medical records, brief patient interviews, and analyzed descriptively. The majority of the patients received first-line chemotherapy (87.80%). Pemetrexed-cisplatin (39.02%) and pemetrexed-carboplatin (19.51%) are the most common first-line therapy, followed by docetaxel (12,20%) as the second-line chemotherapy commonly used by patients. The chemotherapy regimens used in patients were 100% appropriate based on treatment guidelines. 61.11% and 60% of patients experience adverse effects with the first and second line of chemotherapy, respectively. Anemia (63,89%) was the most common delayed adverse effect in the first-line chemotherapy and hair loss (60%) was the most common one in the second-line chemotherapy. The platinum-based chemotherapy is a standard treatment for lung cancer, but its tolerability limits its uses. These findings showed chemotherapy-related adverse effects that need to be considered in choosing the best choice of therapy to optimize the treatment. Therefore, prophylaxis therapy to manage chemotherapy-related adverse effects may be considered in patients with chemotherapy.
Co-Authors Abdul Rahem Abdul Rahem, Abdul Adji P. Setiadi Adji Prayitno Setiadi Aguslina Kirtishanti Brata, Cecilia Cecilia Brata Christanti, Jene Vida Ediyono Ediyono Eko Setiawan Eko Setiawan Eko Setiawan Eko Setiawan Eko Setiawan Febriani, Anna Go, Tjie Kok Halim, Steven Victoria Herawati, Fauna I Komang Agus Bayu Krisnanta I. Setiabudi Jaya, Halim Priyahau Krisnanta, I Komang Agus Bayu Kumalasari, Nunik Dewi Lestiono Lestiono Lie, Putri G. C. E. Mayani, Ni Putu Irma Moh. Firmansah Nani Parfati Nani Parfati, Nani Nunik Dewi Kumalasari Nurul Amalia Putri G. C. E. Lie Rika Yulia Setiadi, Adji Prayitno Setiawan, Eko Steven V. Halim Susanto, Verlita Evelyn Susilo Ari Wardhani Sylvi Irawati Verlita Evelyn Susanto Wibowo, Yosi Irawati Wijono, Heru Yosi I. Wibowo